+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

ER+/HER2 -ve Breast Cancer - Pipeline Insight, 2021

  • ID: 5240442
  • Clinical Trials
  • February 2021
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • AstraZeneca
  • Eisai
  • G1 Therapeutics
  • Genetech/La Roche
  • Sanofi
This “ER+/ HER2 -ve Breast Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in ER+/ HER2 -ve Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

ER+/ HER2 -ve Breast Cancer Understanding


ER+/ HER2 -ve Breast Cancer: Overview


Breast cancer is a disease in which cells in the breast grow out of control. There are different kinds of breast cancer. The kind of breast cancer depends on which cells in the breast turn into cancer. Most breast cancers express the estrogen receptor (ER) receptor and are negative for the human epidermal growth factor receptor 2 (HER2) receptor. The backbone of their systemic therapy consists of hormonal therapies that block the function of ER through various mechanisms. These include blockade of the receptor itself in breast cancer cells, blockade of the production of its major ligand, estradiol, or degradation of the receptor. However, a subset of ER+/HER2- breast cancers, mostly corresponding to the genomic luminal B genotype, are resistant to hormonal manipulations from the outset of therapies.

"ER+/ HER2 -ve Breast Cancer- Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the ER+/ HER2 -ve Breast Cancer pipeline landscape is provided which includes the disease overview and ER+/ HER2 -ve Breast Cancer treatment guidelines. The assessment part of the report embraces, in depth ER+/ HER2 -ve Breast Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, ER+/ HER2 -ve Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence ER+/ HER2 -ve Breast Cancer R&D. The therapies under development are focused on novel approaches to treat/improve ER+/ HER2 -ve Breast Cancer.

ER+/ HER2 -ve Breast Cancer Emerging Drugs Chapters


This segment of the ER+/ HER2 -ve Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

ER+/ HER2 -ve Breast Cancer Emerging Drugs

  • H3B-6545: Eisai
An orally administered selective estrogen receptor alpha (ERa) covalent antagonist that inhibits ERa wild type / ERa mutant. Expected to show an antitumor effect against ER positive / HER2 negative breast cancers.
  • Rintodestrant (G1T48): G1 Therapeutics
Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) in development for the treatment of ER+ breast cancer. Preclinical data have shown rintodestrant to be more potent than fulvestrant, currently the only FDA-approved SERD. The company initiated a phase 1/2a trial of rintodestrant in ER+/HER2 -ve breast cancer.
  • GDC-9545: Genetech/ La Roche
GDC-9545 is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen to limit its function. In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.

ER+/ HER2 -ve Breast Cancer: Therapeutic Assessment


This segment of the report provides insights about the different ER+/ HER2 -ve Breast Cancer drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in ER+/ HER2 -ve Breast Cancer


There are approx. 5+ key companies which are developing the therapies for ER+/ HER2 -ve Breast Cancer. The companies which have their ER+/ HER2 -ve Breast Cancer drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Eisai and others.

The report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
Route of Administration

ER+/ HER2 -ve Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Parenteral
  • Intramuscular
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Small molecules
  • Peptides
  • Polymer
  • Gene Therapy
  • Monoclonal antibodies
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

ER+/ HER2 -ve Breast Cancer: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses ER+/ HER2 -ve Breast Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ER+/ HER2 -ve Breast Cancer drugs.

ER+/ HER2 -ve Breast Cancer Report Insights

  • ER+/ HER2 -ve Breast Cancer Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

ER+/ HER2 -ve Breast Cancer Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing ER+/ HER2 -ve Breast Cancer drugs?
  • How many ER+/ HER2 -ve Breast Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ER+/ HER2 -ve Breast Cancer?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the ER+/ HER2 -ve Breast Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for ER+/ HER2 -ve Breast Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Eisai
  • G1 Therapeutics
  • Genetech/La Roche
  • Sanofi
  • AstraZeneca

Key Products

  • H3B-6545
  • G1T48
  • GDC-9545
  • SAR439859
  • AZD9833
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca
  • Eisai
  • G1 Therapeutics
  • Genetech/La Roche
  • Sanofi
Introduction

Executive Summary

ER+/ HER2 - ve Breast Cancer: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
ER+/ HER2 - ve Breast Cancer - Analytical Perspective

In-depth Commercial Assessment
  • ER+/ HER2 - ve Breast Cancer companies' collaborations, Licensing, Acquisition - Deal Value Trends
ER+/ HER2 - ve Breast Cancer Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Rintodestrant (G1T48): G1 Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Pre-clinical and Discovery Stage Products
  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
ER+/ HER2 - ve Breast Cancer Key Companies

ER+/ HER2 - ve Breast Cancer Key Products

ER+/ HER2 - ve Breast Cancer - Unmet Needs

ER+/ HER2 - ve Breast Cancer - Market Drivers and Barriers

ER+/ HER2 - ve Breast Cancer - Future Perspectives and Conclusion

ER+/ HER2 - ve Breast Cancer Analyst Views

ER+/ HER2 - ve Breast Cancer Key Companies

Appendix

List of Tables
Table 1 Total Products for ER+/ HER2 -ve Breast Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for ER+/ HER2 -ve Breast Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Eisai
  • G1 Therapeutics
  • Genetech/La Roche
  • Sanofi
  • AstraZeneca
Note: Product cover images may vary from those shown
Adroll
adroll